Comparative Pharmacology
Head-to-head clinical analysis: NYMALIZE versus PLENDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYMALIZE versus PLENDIL.
NYMALIZE vs PLENDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NMDA receptor antagonist; acts as a neuroprotective agent by reducing excitotoxicity and modulating calcium influx. Also binds to sigma-1 receptors, possibly contributing to neuroprotection.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
10 mg (5 mL) intravenously over 5-15 minutes, may repeat after 15 minutes if needed; followed by continuous infusion of 0.9-2.0 mg/hour (5-10 mL/hour).
Initial: 5 mg orally once daily. Maintenance: 2.5–10 mg orally once daily. Maximum: 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8–9 hours (range 5–12 hours) in patients with subarachnoid hemorrhage. In elderly or hepatically impaired patients, half-life may be prolonged. Clinically, steady-state is achieved after 3–5 days of oral dosing.
Terminal elimination half-life 2-5 hours in healthy adults; 7-12 hours in patients with hepatic impairment or advanced age
Nymalize (nimodipine) is primarily eliminated via hepatic metabolism. Approximately 50% of the dose is excreted in urine as metabolites and <1% as unchanged drug. Fecal excretion accounts for ~20% of metabolites. Less than 1% is excreted unchanged in bile. Renal clearance is negligible for parent compound.
Renal (approximately 70% as metabolites, <0.5% unchanged); fecal (approximately 10%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker